Alimera Sciences in brief
Alimera Sciences is an unlisted company in the Pharmaceutical industry, based in Alpharetta, Georgia, USA. It was founded in 2003. In the year to December 2023 it had sales of $81 M and a net loss of $20 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Alimera Sciences
Alimera Sciences, Inc. was a biopharmaceutical sales company based in Alpharetta, Georgia that specialized in the commercialization and sales of prescription ophthalmic pharmaceuticals. The company's main selling focus was on diseases affecting the back of the eye, or retina.
In September, 2024, ANI Pharmaceuticals, Inc. announced that it had completed its purchase of the company.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Alimera Sciences timeline
- 2003
- 🏁· approximateFounded
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2010
- 🔔· approximateInitial public offering on Nasdaq as ALIM
- 2023
- 💰Record revenue of $81 millionFY2023, the highest of the 6 years on record.
Events of Alimera Sciences from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Alimera Sciences
- Acquisitions and changes
- Taken over: the company reported a change in control and the delisting of its shares to the SEC on 16 September 2024 (Form 8-K).
Market cap history
World rank over time
Rank in USA: #4,193 (Jan 2020) · #4,386 (Jan 2021) · #5,112 (Jan 2022) · #5,407 (Dec 2022) · #5,026 (Jul 2023) · #3,220 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -24.9%
- Operating margin
- -2.4%
- Return on equity
- -43.6%
- Liabilities / assets
- 69.9%
- Net debt
- $33M
- Revenue growth
- +49.2%
- R&D / revenue
- 20.6%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2023 | $81M | +49.2% | $-2M | $-20M | -24.9% |
| Dec 2022 | $54M | -8.3% | $-12M | $-18M | -33.5% |
| Dec 2021 | $59M | +16.2% | $-0M | $-4M | -7.4% |
| Dec 2020 | $51M | -5.8% | $-1M | $-5M | -10.5% |
| Dec 2019 | $54M | +15.8% | $-5M | $-10M | -19.4% |
| Dec 2018 | $47M | +29.8% | $-10M | $-16M | -35.2% |
| Dec 2017 | $36M | +4.6% | $-16M | $-22M | -61.3% |
| Dec 2016 | $34M | — | $-28M | $-33M | -96.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2023 | $-14M | $0M | $-15M | $-0.84 | — |
| Dec 2022 | $-10M | $0M | $-10M | $-2.59 | — |
| Dec 2021 | $-3M | $1M | $-4M | $-0.66 | — |
| Dec 2020 | $-2M | $1M | $-3M | $-1.04 | — |
| Dec 2019 | $-4M | $0M | $-4M | $-2.19 | — |
| Dec 2018 | $-12M | $0M | $-12M | $3.71 | — |
| Dec 2017 | $-13M | $0M | $-13M | $-0.33 | — |
| Dec 2016 | $-25M | $0M | $-25M | $-0.63 | — |
Quarterly results
Latest quarter to Jun 2024: revenue $27M (+53.9% on a year earlier), net income $-3M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Sep 16, 20248-KCurrent reportAgreement ended · Acquisition or disposal completed · Listing notice · Change in control · Directors or officers changed · Bylaws amended · Other events
- Sep 11, 20248-KCurrent reportOther events
- Sep 10, 20248-KCurrent reportDirectors or officers changed · Shareholder vote
- Sep 10, 20248-KCurrent reportOther events
- Aug 7, 202410-QQuarterly report · period to Jun 2024
- Aug 6, 20248-KCurrent reportResults of operations
- Jul 23, 20248-KCurrent reportMaterial agreement
- Jun 24, 20248-KCurrent reportMaterial agreement
- Jun 24, 20248-KCurrent reportMaterial agreement · Regulation FD disclosure · Other events
- May 14, 202410-QQuarterly report · period to Mar 2024
- May 14, 20248-KCurrent reportResults of operations
- Apr 29, 202410-K/AAnnual report (amended) · period to Dec 2023
Official filings of Alimera Sciences with the US Securities and Exchange Commission.
Annual results
- Revenue
- $81 M
- Operating income
- $-2 M
- Net income
- $-20 M
For year ending December-2023 · source: SEC filing
Balance sheet
- Total assets
- $154 M
- Total liabilities
- $107 M
- Total equity
- $46 M
As of December-2023
Insider trading at Alimera Sciences#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David HollandChief Marketing Officer & SVP | Disposal to the company | -187,756 | — | — | 0 | Form 4 |
| filed | Peter J. Pizzo IIIDirector | Disposal to the company | -500 | — | — | 0 | Form 4 |
| filed | Jason M. WernerChief Operating Officer | Disposal to the company | -225,000 | — | — | 225,000 | Form 4 |
| filed | Philip AshmanPresident of Int'l Operations | Disposal to the company | -118,274 | — | — | 0 | Form 4 |
| filed | Caligan Partners LP10% owner | Otherindirect | -16.84 M | — | — | 0 | Form 4 |
| filed | John SnisarenkoDirector | Disposal to the company | -10,000 | — | — | 0 | Form 4 |
| filed | Richard S. Eiswirth Jr.President and CEO | Disposal to the company | -324,018 | — | — | 0 | Form 4 |
| filed | Velan Capital Management LLC10% owner | Disposal to the companyindirect | -9.43 M | — | — | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Alimera Sciences#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 15-for-1 split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2023 | Q4 2023 | $0M |
| Q3 2023 | Q3 2023 | $0M |
| Q2 2023 | Q2 2023 | $0M |
| Q1 2023 | Q1 2023 | $0.3M |
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Alimera Sciences scorecard#
Passes 4 of the 16 checks that could be worked out: strongest in growth (3 of 6), weakest in profitability (0 of 5). Fiscal year 2023.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth3 of 6
- ✓Revenue grew in the newest year49.2%Revenue up 49.2% in fiscal 2023.
- ✓Revenue up more than 5% a year over three years16.7%16.7% a year over the three years to fiscal 2023.
- ✓Faster growth over three years than its peers' median16.7%16.7% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✗Earnings per share grew in the newest year-0.84 vs -2.59Diluted EPS -0.84 in fiscal 2023 against -2.59 the year before (report's currency).
- ✗Net income higher than five years earlier-$20 M-$20 M in fiscal 2023 against -$16 M in 2018.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2023.
Profitability0 of 5
- ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2023.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2023.
- ✗Operating margin above its peers' median-2.4%-2.4% against Pharmaceutical's median of 1.8% (74 companies).
- ✗Return on equity above 15%-158.8%-158.8% in fiscal 2023.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-2.4%-2.4% in fiscal 2023 against -1.0% in 2020.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.39 at the end of fiscal 2023.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-0.2×Operating income -0.2 times interest in fiscal 2023.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2023.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 2
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year265.3%Diluted shares up 265.3% in fiscal 2023.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- ✗Free cash flow covers dividends and buybacks-$15 MFree cash flow -$15 M against $0 M paid out in fiscal 2023.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Alimera Sciences: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 | FY 2014to Dec 31, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 81+49.2%100% | 54−8.3%100% | 59+16.2%100% | 51−5.8%100% | 54+15.8%100% | 47r47+29.8%100% | 36+4.6%100% | 34+53.0%100% | 22+166%100% | 8.4—100% | |
| Cost of revenue | — | — | — | — | — | — | 3.4+46.7%9.6% | 2.3+33.0%6.8% | 1.8+22.2%7.9% | 1.4—17.1% | |
| Gross profit | 70+51.5%86.6% | 46−11.2%85.3% | 52+18.5%88.1% | 44−7.3%86.3% | 47+11.9%87.7% | 42+30.2%90.8% | 32+1.5%90.4% | 32+54.7%93.2% | 21+196%92.1% | 7.0—82.9% | |
| Research and development | 17+2.5%20.6% | 16+17.8%30.0% | 14+42.5%23.3% | 9.7−12.0%19.0% | 11−2.5%20.4% | 11−12.2%24.2% | 13+3.8%35.8% | 12−16.6%36.0% | 15+25.6%66.1% | 12r11—140% | |
| Selling and marketing | 28+7.5%34.6% | 26+12.6%48.0% | 23+13.2%39.1% | 20−20.6%40.1% | 26—47.6% | — | — | — | — | — | |
| General and administrative | 19+44.0%22.9% | 13+0.8%23.8% | 13+9.6%21.6% | 12−12.2%22.9% | 13r14−8.6%24.6% | 15+11.4%31.2% | 13−14.6%36.3% | 15+7.6%44.5% | 14+14.7%63.2% | 12—147% | |
| Operating expenses | 72+24.3%89.0% | 58+10.7%107% | 52+17.6%88.4% | 44−15.6%87.3% | 53+1.2%97.5% | 52+6.2%112% | 49−18.2%136% | 60+0.3%174% | 60+49.5%266% | 40—474% | |
| Operating income | −1.9—−2.4% | −12—−21.5% | −0.2—−0.3% | −0.5—−1.0% | −5.3—−9.8% | −9.7—−20.8% | −16—−45.8% | −28—−81.1% | −39—−174% | −33—−391% | |
| Interest expense and finance costs | 10+73.2%12.6% | 5.9+8.6%10.9% | 5.4+0.6%9.2% | 5.4+10.5%10.6% | 4.9+2.0%9.0% | 4.8−14.4%10.2% | 5.6+7.7%15.5% | 5.2+10.3%15.1% | 4.7+125%20.9% | 2.1—24.8% | |
| Income before tax | −20—−24.8% | −18—−33.4% | −3.9—−6.7% | −5.4—−10.6% | −10—−19.0% | −16—−34.9% | −22—−60.8% | −33—−96.1% | −31—−136% | −36—−424% | |
| Income tax | 0.1+204%0.1% | 0.0−93.6%0.1% | 0.4—0.7% | −0.1−131%−0.1% | 0.2+104%0.4% | 0.1−35.0%0.2% | 0.2−5.2%0.5% | 0.2+32.3%0.5% | 0.1−25.3%0.6% | 0.2—2.1% | |
| Net income attributable to shareholders | −20—−24.9% | −18—−33.5% | −4.4—−7.4% | −5.3—−10.5% | −10—−19.4% | −16—−35.2% | −22—−61.3% | −33—−96.6% | −31—−137% | −36—−426% | |
| Earnings per share, basic | -0.84—— | -2.59—— | -0.66—— | -1.04—— | -2.19−159%— | 3.74r0.25—— | -0.33—— | -0.63—— | -0.69—— | -0.91—— | |
| Earnings per share, diluted | -0.84—— | -2.59—— | -0.66—— | -1.04—— | -2.19−159%— | 3.71r0.25—— | -0.33—— | -0.63—— | -0.69—— | -0.91—— | |
| Shares, weighted average (basic) | 26+265%— | 7.0+6.1%— | 6.6—— | — | 4.8+2.2%— | 4.7r70−93.0%— | 67—— | — | — | — | |
| Shares, weighted average (diluted) | 26+265%— | 7.0+6.1%— | 6.6+28.9%— | 5.1+7.3%— | 4.8+1.2%— | 4.7r71−93.0%— | 67+26.9%— | 53+18.8%— | 44+10.0%— | 40—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 12+129%7.9% | 5.3−68.1%12.4% | 17+47.3%28.2% | 11+18.9%22.0% | 9.4−27.7%18.7% | 13−45.8%24.1% | 24−22.3%40.2% | 31−0.3%44.1% | 31−59.5%44.1% | 77—70.6% | |
| Receivables | 35+76.1%22.5% | 20+2.5%46.0% | 19+11.2%32.7% | 17−11.0%33.8% | 19+12.0%38.4% | 17+50.9%31.9% | 11−17.4%19.1% | 14+41.2%19.7% | 9.8+1053%13.9% | 0.9—0.8% | |
| Inventory | 1.9+17.1%1.2% | 1.6−40.1%3.8% | 2.7−2.4%4.6% | 2.7+97.6%5.4% | 1.4−42.2%2.8% | 2.4+59.5%4.4% | 1.5+238%2.5% | 0.4−71.3%0.6% | 1.6−10.5%2.2% | 1.7—1.6% | |
| Other current assets | 3.9+35.2%2.5% | 2.9−24.1%6.8% | 3.8+2.4%6.5% | 3.7+45.0%7.3% | 2.6+21.6%5.1% | 2.1−7.4%3.9% | 2.3+8.1%3.8% | 2.1−21.8%3.0% | 2.7−16.6%3.8% | 3.2—3.0% | |
| Current assets | 52+78.2%34.1% | 29−30.2%69.0% | 42+20.8%72.0% | 35+6.6%68.6% | 33−6.0%65.1% | 35−11.4%64.4% | 39−17.0%65.6% | 47+5.0%67.5% | 45−45.3%64.1% | 83r83—75.9% | |
| Property, plant and equipment | 2.5−2.3%1.6% | 2.5−9.3%5.9% | 2.8+69.9%4.8% | 1.6+74.3%3.2% | 0.9−30.6%1.9% | 1.4−3.9%2.5% | 1.4−21.1%2.4% | 1.8−30.0%2.5% | 2.6+54.4%3.6% | 1.7—1.5% | |
| Right-of-use (leased) assets | 1.1−19.4%0.7% | 1.4−18.4%3.3% | 1.7+138%2.9% | 0.7−35.0%1.4% | 1.1—2.2% | — | — | — | — | — | |
| Other intangible assets | 97+987%63.4% | 9.0−17.8%21.0% | 11−15.1%18.6% | 13−13.2%25.2% | 15−11.6%29.4% | 17−10.4%30.9% | 19−9.4%31.1% | 21−8.6%29.3% | 23−7.9%32.0% | 24—22.5% | |
| Total assets | 154+260%100% | 43−27.2%100% | 59+15.1%100% | 51+1.1%100% | 50−7.0%100% | 54−9.7%100% | 60−14.7%100% | 70−0.4%100% | 70−35.1%100% | 109r109—100% | |
| Accounts payable | 8.3−18.2%5.4% | 10+15.9%23.7% | 8.7+16.7%14.9% | 7.5+5.4%14.7% | 7.1+11.4%14.1% | 6.4+7.6%11.7% | 5.9+18.4%9.9% | 5.0+24.6%7.1% | 4.0−20.3%5.7% | 5.0—4.6% | |
| Debt due within a year | — | — | — | — | 0—0.0% | 0—0.0% | — | — | — | — | |
| Current liabilities | 22−44.8%14.3% | 40+216%93.3% | 13+2.0%21.5% | 12+2.5%24.3% | 12+17.7%23.9% | 10+5.8%18.9% | 9.7+6.0%16.1% | 9.1−77.2%13.0% | 40+281%56.7% | 10—9.6% | |
| Long-term debt | — | — | — | — | 39+2.1%76.8% | 38—70.0% | — | — | — | — | |
| Lease liabilities (non-current) | 1.8−19.5%1.2% | 2.3−17.1%5.3% | 2.7+524%4.7% | 0.4−47.2%0.9% | 0.8—1.6% | — | — | — | — | — | |
| Total liabilities | 107+69.3%69.9% | 63—149% | — | — | — | — | — | — | — | — | |
| Retained earnings | −418—−273% | −415—−975% | −397—−679% | −393—−773% | −388—−770% | −377—−697% | −399—−666% | −377—−537% | −344—−488% | −313—−288% | |
| Shareholders' equity | 46—30.1% | −21—−48.8% | −2.6—−4.5% | −8.0—−15.7% | −4.4−263%−8.8% | 2.7−81.8%5.0% | 15r15−41.7%24.9% | 26−2.8%36.4% | 26−46.8%37.3% | 50—45.6% | |
| Total liabilities and equity | 154+260%100% | 43−27.2%100% | 59+15.1%100% | 51+1.1%100% | 50−7.0%100% | 54−9.7%100% | 60−14.7%100% | 70−0.4%100% | 70−35.1%100% | 109r109—100% | |
| Shares outstanding | 52+648%— | 7.0+0.9%— | 6.9+21.3%— | 5.7+15.2%— | 5.0+6.3%— | 4.7r70−93.2%— | 69+6.6%— | 65+44.1%— | 45+1.5%— | 44—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 8.7+223%10.8% | 2.7+4.9%5.0% | 2.6−3.6%4.4% | 2.7+1.3%5.3% | 2.6−0.2%4.9% | 2.6−1.5%5.7% | 2.7−3.0%7.5% | 2.8+8.3%8.1% | 2.6+288%11.4% | 0.7—7.8% | |
| Share-based compensation | 1.4+57.7%1.8% | 0.9−8.7%1.7% | 1.0−25.1%1.7% | 1.3−45.8%2.6% | 2.5−44.3%4.6% | 4.4−11.4%9.5% | 5.0+1.9%13.9% | 4.9−2.9%14.2% | 5.0+30.8%22.4% | 3.9r3.8—45.7% | |
| Cash from operating activities | −14—−17.7% | −10.0—−18.4% | −3.2—−5.5% | −2.2—−4.3% | −4.2—−7.7% | −12—−24.8% | −13—−35.8% | −25—−73.1% | −45—−202% | −24—−289% | |
| Capital expenditure | −0.3—−0.3% | −0.3—−0.5% | −0.6—−1.1% | −0.6—−1.2% | −0.2—−0.3% | −0.2—−0.4% | −0.2—−0.7% | −0.2—−0.5% | −0.5—−2.0% | −0.8—−10.0% | |
| Intangible assets bought | −75—−93.2% | — | — | — | — | — | — | — | 0—0.0% | −25—−297% | |
| Cash from investing activities | −76—−93.5% | −0.3—−0.5% | −0.6—−1.1% | −0.6—−1.2% | −0.2—−0.3% | −0.2—−0.4% | −0.2—−0.7% | −0.2—−0.5% | −0.5—−2.0% | −26—−307% | |
| Debt issued | 23—27.9% | — | — | 4.3−89.9%8.4% | 43+6.3%78.8% | 40—85.8% | 0—0.0% | — | — | — | |
| Shares issued | 2.4+2728%3.0% | 0.1−99.2%0.2% | 10+20480%17.1% | 0.0−94.6%0.1% | 0.9+987%1.7% | 0.1−98.6%0.2% | 6.1−78.1%16.9% | 28+2671%80.9% | 1.0−97.3%4.5% | 38—446% | |
| Shares bought back | −0.3—−0.4% | — | — | — | — | — | — | — | — | — | |
| Dividends paid | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Cash from financing activities | 96—119% | −0.3−103%−0.6% | 9.8+153%16.6% | 3.9+347%7.6% | 0.9−8.5%1.6% | 1.0−83.4%2.0% | 5.7r5.7−77.5%15.9% | 25+3968%74.1% | 0.6−99.5%2.8% | 115—1362% | |
| Exchange-rate effect on cash | 0.1—0.1% | −0.7—−1.3% | −0.7−195%−1.1% | 0.7—1.4% | −0.2—−0.3% | −0.2−151%−0.5% | 0.5r0.5—1.3% | −0.2—−0.7% | −0.4—−1.9% | −0.5—−6.3% | |
| Change in cash | 6.8—8.4% | −11−312%−20.8% | 5.3+197%9.0% | 1.8—3.5% | −3.6—−6.7% | −11—−23.7% | −6.9r−6.9—−19.2% | −0.1—−0.3% | −46−171%−203% | 64—761% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 | Q4 FY2022to Dec 31, 2022 | Q3 FY2022to Sep 30, 2022 | Q2 FY2022to Jun 30, 2022 | Q1 FY2022to Mar 31, 2022 | Q4 FY2021to Dec 31, 2021 | Q3 FY2021to Sep 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 100+69.8%100% | 27+54.0%100% | 23+69.9%100% | 26*+87.5%100% | 23+71.8%100% | 18+20.1%100% | 14+13.9%100% | 14*+0.5%100% | 14+11.9%100% | 15—100% | 12—100% | 14*—100% | 12—100% | |
| Gross profit | 86+71.8%86.4% | 23+53.3%85.8% | 20+70.7%85.4% | 23*+90.5%86.2% | 21+77.8%88.2% | 15+21.5%86.2% | 12+12.7%85.0% | 12*−0.7%84.9% | 12+10.8%85.2% | 12—85.2% | 10—85.9% | 12*—85.9% | 10—86.1% | |
| Research and development | 17+5.5%17.5% | 4.3+16.9%15.8% | 4.4+4.7%19.0% | 4.8*+12.7%18.1% | 4.0−9.8%17.3% | 3.6−7.2%20.8% | 4.2+16.2%30.7% | 4.2*+13.7%30.2% | 4.5+36.8%33.0% | 3.9—26.9% | 3.6—30.1% | 3.7*—26.6% | 3.3—27.0% | |
| Selling and marketing | 33+35.9%33.4% | 8.5+32.3%31.5% | 9.1+56.5%39.5% | 7.8*+34.7%29.5% | 7.9+22.1%34.0% | 6.4−6.3%36.7% | 5.8−15.3%42.8% | 5.8*−19.6%41.1% | 6.5+13.1%47.8% | 6.9—47.0% | 6.9—57.6% | 7.2*—51.4% | 5.8—47.3% | |
| General and administrative | 23+49.7%22.9% | 7.4+68.7%27.3% | 5.4+30.2%23.6% | 6.4*+91.3%24.2% | 3.6+7.6%15.4% | 4.4+48.5%24.9% | 4.2+28.7%30.8% | 3.3*+4.3%23.8% | 3.4+19.4%24.7% | 2.9—20.2% | 3.2—27.2% | 3.2*—22.9% | 2.8—23.1% | |
| Operating expenses | 86+42.8%86.2% | 23+42.4%86.1% | 22+48.2%95.4% | 22*+56.7%83.5% | 19+25.0%80.3% | 16+13.2%93.1% | 15+3.2%109% | 14*−5.0%99.9% | 15+20.2%110% | 14—98.7% | 14—121% | 15*—106% | 12—103% | |
| Operating income | 0.2—0.2% | −0.1—−0.3% | −2.3—−10.0% | 0.7*—2.8% | 1.9—7.9% | −1.2—−6.9% | −3.3—−24.4% | −2.1*—−15.0% | −3.4—−25.1% | −2.0—−13.5% | −4.1—−34.9% | −2.8*—−19.7% | −2.0—−16.6% | |
| Interest expense and finance costs | 14+111%13.8% | 3.2+86.1%11.7% | 3.7+124%16.2% | 4.8*+191%18.1% | 2.1+38.0%8.9% | 1.7+22.5%9.7% | 1.7+22.2%12.3% | 1.6*+19.9%11.6% | 1.5+10.3%11.0% | 1.4—9.5% | 1.4—11.5% | 1.4*—9.8% | 1.4—11.2% | |
| Income before tax | −15—−14.8% | −3.4—−12.4% | −6.3—−27.3% | −3.8*—−14.3% | −1.3—−5.6% | −10—−57.0% | −5.0—−36.7% | −3.8*—−27.0% | −5.2—−38.6% | −3.1—−21.2% | −6.0—−50.1% | −4.1*—−29.7% | −4.4—−35.8% | |
| Income tax | −0.0—−0.0% | −0.0−272%−0.2% | −0.0—−0.1% | 0.0*—0.0% | 0.1+342%0.2% | 0.0+47.1%0.1% | — | −0.0*—−0.0% | 0.0—0.1% | 0.0—0.1% | — | −0.0*—−0.2% | −0.2—−1.4% | |
| Net income attributable to shareholders | −15—−14.7% | −3.3—−12.3% | −6.3—−27.2% | −3.8*—−14.4% | −1.4—−5.8% | −10—−57.2% | −5.0—−36.7% | −3.8*—−26.9% | −5.3—−38.7% | −3.1—−21.3% | −6.0—−50.1% | −4.1*—−29.4% | −4.2—−34.4% | |
| Earnings per share, basic | — | -0.06—— | -0.12—— | — | -0.06—— | -1.32—— | -0.71—— | — | -0.75—— | -0.45—— | -0.85—— | — | -0.60—— | |
| Earnings per share, diluted | — | — | -0.12—— | — | -0.06—— | -1.32—— | -0.71—— | — | -0.75—— | -0.45—— | -0.85—— | — | -0.60—— | |
| Shares, weighted average (basic) | 54+572%— | 54+572%— | 54+673%— | — | 32+359%— | 8.1+15.6%— | 7.0+0.6%— | — | 7.0+1.0%— | 7.0—— | 7.0—— | — | 6.9—— | |
| Shares, weighted average (diluted) | — | — | 54+673%— | — | 32+359%— | 8.1+15.6%— | 7.0+0.6%— | — | 7.0+1.0%— | 7.0—— | 7.0—— | — | 6.9—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 11—7.2% | 11−42.3%7.2% | 14+9.4%9.4% | 12+129%7.9% | 8.3+50.3%5.4% | 19+139%12.1% | 13+31.6%27.1% | 5.3−68.1%12.4% | 5.5−74.4%12.7% | 7.9—16.5% | 9.9—19.9% | 17—28.2% | 22—35.8% | |
| Receivables | 37—24.7% | 37+64.1%24.7% | 34+85.7%22.4% | 35+76.1%22.5% | 34+77.3%22.0% | 23+11.2%14.6% | 18−1.8%38.2% | 20+2.5%46.0% | 19+18.1%44.1% | 20—42.7% | 19—37.6% | 19—32.7% | 16—27.0% | |
| Inventory | 3.5—2.3% | 3.5+227%2.3% | 2.2+81.6%1.4% | 1.9+17.1%1.2% | 1.8−1.5%1.1% | 1.1−36.3%0.7% | 1.2−50.4%2.5% | 1.6−40.1%3.8% | 1.8−22.4%4.1% | 1.7—3.5% | 2.5—4.9% | 2.7—4.6% | 2.3—3.8% | |
| Other current assets | 4.0—2.7% | 4.0+12.4%2.7% | 3.7+26.9%2.4% | 3.9+35.2%2.5% | 4.4+33.2%2.8% | 3.6+11.3%2.3% | 2.9−17.9%6.0% | 2.9−24.1%6.8% | 3.3−7.7%7.6% | 3.2—6.7% | 3.5—7.1% | 3.8—6.5% | 3.6—5.9% | |
| Current assets | 55—36.8% | 55+20.4%36.8% | 54+52.7%35.7% | 52+78.2%34.1% | 48+62.6%31.4% | 46+39.2%29.7% | 36+2.7%74.0% | 29−30.2%69.0% | 30−31.8%68.5% | 33—69.5% | 35—69.6% | 42—72.0% | 44—72.6% | |
| Property, plant and equipment | 2.3—1.5% | 2.3−7.6%1.5% | 2.4−1.7%1.6% | 2.5−2.3%1.6% | 2.4−0.2%1.6% | 2.5+1.9%1.6% | 2.4−11.0%5.0% | 2.5−9.3%5.9% | 2.4+47.0%5.6% | 2.4—5.1% | 2.7—5.4% | 2.8—4.8% | 1.7—2.8% | |
| Right-of-use (leased) assets | 1.0—0.7% | 1.0−22.0%0.7% | 1.1−20.8%0.7% | 1.1−19.4%0.7% | 1.2−17.4%0.8% | 1.3−16.0%0.8% | 1.3−17.6%2.8% | 1.4−18.4%3.3% | 1.4−17.2%3.3% | 1.5—3.2% | 1.6—3.3% | 1.7—2.9% | 1.7—2.9% | |
| Other intangible assets | 92—60.9% | 92−12.7%60.9% | 94+1014%62.0% | 97+987%63.4% | 102+980%66.1% | 105+956%67.7% | 8.5−18.6%17.6% | 9.0−17.8%21.0% | 9.4−17.0%21.8% | 9.9—20.9% | 10—20.9% | 11—18.6% | 11—19.0% | |
| Total assets | 150—100% | 150−2.9%100% | 152+216%100% | 154+260%100% | 154+255%100% | 155+226%100% | 48−3.4%100% | 43−27.2%100% | 43−27.7%100% | 48—100% | 50—100% | 59—100% | 60—100% | |
| Accounts payable | 10—6.8% | 10+27.0%6.8% | 10+6.6%6.8% | 8.3−18.2%5.4% | 6.2−28.7%4.0% | 8.0+5.6%5.2% | 9.7+46.4%20.0% | 10+15.9%23.7% | 8.7+17.1%20.0% | 7.6—16.0% | 6.6—13.2% | 8.7—14.9% | 7.4—12.4% | |
| Current liabilities | 20—13.2% | 20+39.3%13.2% | 21+46.7%13.6% | 22−44.8%14.3% | 18−47.9%11.5% | 14−44.0%9.2% | 14−16.7%29.4% | 40+216%93.3% | 34+198%78.3% | 25—53.5% | 17—34.1% | 13—21.5% | 11—19.0% | |
| Lease liabilities (non-current) | 1.7—1.1% | 1.7−16.7%1.1% | 1.8−18.3%1.2% | 1.8−19.5%1.2% | 1.9−18.4%1.2% | 2.0−18.3%1.3% | 2.2−17.7%4.5% | 2.3−17.1%5.3% | 2.4+56.8%5.4% | 2.5—5.2% | 2.6—5.2% | 2.7—4.7% | 1.5—2.5% | |
| Total liabilities | 112—74.2% | 112—74.2% | 112—73.3% | 107+69.3%69.9% | — | — | — | 63—149% | — | — | — | — | — | |
| Retained earnings | −428—−285% | −428—−285% | −425—−279% | −418—−273% | −415—−269% | −413—−266% | −402—−834% | −415—−975% | −412—−948% | −406—−854% | −403—−808% | −397—−679% | −393—−655% | |
| Shareholders' equity | 39—25.8% | 39−16.1%25.8% | 41—26.7% | 46—30.1% | 49—31.7% | 46—29.8% | −19—−39.2% | −21—−48.8% | −18−1304%−41.6% | −12—−25.9% | −8.6—−17.2% | −2.6—−4.5% | 1.5—2.5% | |
| Total liabilities and equity | 150—100% | 150−2.9%100% | 152+216%100% | 154+260%100% | 154+255%100% | 155+226%100% | 48−3.4%100% | 43−27.2%100% | 43−27.7%100% | 48—100% | 50—100% | 59—100% | 60—100% | |
| Shares outstanding | 52—— | 52+495%— | 52+609%— | 52+648%— | 52+649%— | 8.8+25.8%— | 7.4+5.7%— | 7.0+0.9%— | 7.0+1.0%— | 7.0—— | 7.0—— | 6.9—— | 6.9—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 12+218%12.4% | 3.1+65.8%11.5% | 3.1+353%13.4% | 3.0*+345%11.6% | 3.2+376%13.5% | 1.9+179%10.6% | 0.7−1.2%5.0% | 0.7*+3.6%4.9% | 0.7+2.3%4.9% | 0.7—4.6% | 0.7—5.8% | 0.7*—4.7% | 0.6—5.3% | |
| Share-based compensation | — | — | 0.8+274%3.7% | 0.8*+330%3.1% | 0.2*+32.4%0.8% | 0.2*−19.7%1.2% | 0.2−27.6%1.7% | 0.2*−21.8%1.3% | 0.1*−41.8%1.0% | 0.3*—1.8% | 0.3—2.6% | 0.2*—1.7% | 0.2*—2.0% | |
| Cash from operating activities | −5.6—−5.6% | 1.0*—3.8% | −0.6—−2.5% | 3.8*—14.3% | −9.8*—−42.1% | −6.0*—−34.2% | −2.2—−16.3% | −0.3*—−1.8% | −1.9*—−14.1% | −1.6*—−10.9% | −6.2—−52.2% | −4.7*—−33.5% | −2.7*—−22.5% | |
| Capital expenditure | −0.2—−0.2% | −0.1*—−0.4% | −0.0—−0.1% | −0.1*—−0.3% | −0.0*—−0.0% | −0.2*—−0.9% | −0.0—−0.1% | −0.1*—−0.6% | −0.1*—−1.0% | — | −0.1—−1.3% | −0.1*—−0.9% | −0.3*—−2.6% | |
| Intangible assets bought | — | — | — | 0*—0.0% | 0*—0.0% | — | — | — | — | — | — | — | — | |
| Cash from investing activities | −0.2—−0.2% | −0.1*—−0.4% | −0.0—−0.1% | −0.1*—−0.3% | −0.0*—−0.0% | −75*−69946%−430% | −0.0—−0.1% | −0.1*—−0.6% | −0.1*—−1.0% | 0.1*—0.7% | −0.1—−1.3% | −0.1*—−0.9% | −0.3*—−2.6% | |
| Debt issued | 5.0—5.0% | 0*−100%0.0% | 5.0+100%21.7% | 0*—0.0% | 0*—0.0% | 20*—114% | 2.5—18.5% | — | — | — | — | — | — | |
| Shares issued | — | — | — | 0*−100%0.0% | 0*—0.0% | — | — | 0.0*+7.1%0.3% | 0*—0.0% | — | — | 0.0*—0.3% | 0*—0.0% | |
| Shares bought back | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | −0.3—−2.3% | — | — | — | — | — | — | |
| Cash from financing activities | −2.0−102%−2.0% | −4.3*−105%−16.0% | 3.0−70.3%12.9% | −0.1*—−0.3% | −0.5*−1093%−2.3% | 87*—497% | 10.0—73.8% | −0.2*—−1.4% | 0.1*—0.4% | −0.1*—−0.7% | −0.1—−0.5% | −0.0*—−0.1% | −0.0*—−0.4% | |
| Exchange-rate effect on cash | — | — | −0.1−476%−0.5% | 0.2*−42.4%0.6% | −0.1*—−0.5% | −0.0*—−0.0% | 0.0—0.2% | 0.3*—2.1% | −0.4*—−2.6% | −0.5*—−3.4% | −0.1—−1.2% | −0.2*—−1.4% | −0.2*—−1.4% | |
| Change in cash | −7.9−173%−8.0% | −3.5*−161%−12.9% | 2.3−71.1%9.8% | 3.8*—14.3% | −10*—−44.9% | 5.7*—32.4% | 7.8—57.7% | −0.2*—−1.7% | −2.3*—−17.3% | −2.1*—−14.3% | −6.6—−55.2% | −5.0*—−35.9% | −3.3*—−26.8% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Alimera Sciences#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Delisting notice 1 · Taken over and delisted 1 · Change in control 2 · Acquisition or sale completed 2 · Directors and officers 13 · Material agreement 7 · Agreement ended 1 · New debt 3 · Unregistered share sale 4 · Shareholder rights changed 5 · Bylaws or fiscal year changed 4 · Shareholder vote 2 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersAgreement endedShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementResults announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Change in controlUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officersUnregistered share saleShareholder rights changedShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completedDirectors and officersMaterial agreementNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting noticeDirectors and officersMaterial agreementNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debt | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 16, 2024
Acquisitions and funding#
5 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2023 | $81 M | No. 5 | $50 to $250 million | 16 | equity, options | SEC |
| Apr 2021 | $10 M | No. 4 | $10 to $50 million | 1 | equity | SEC |
| Jan 2014 | $38 M | No. 3 | $10 to $50 million | 21 | equity | SEC |
| Oct 2012 | $40 M | No. 2 | $10 to $50 million | — | equity, options | SEC |
| Aug 2009 | $5 M | No. 1 | $2 to $10 million | 25 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
FDA drug approvals: Alimera Sciences#
2 approved applications held; 1 approvals and 0 new uses in 2018.
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (ALIMERA SCIENCES INC), so they follow acquisitions
How Alimera Sciences compares in Pharmaceutical
- Revenue$81 M · higher than 20% of 324
- Net margin-24.9% · higher than 13% of 313
- Revenue growth49.2% · higher than 90% of 107
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Alimera Sciences🇺🇸 | $209 M | — | -24.9% | +49.2% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2023
- Balance sheet:
- As of December-2023
- Profile updated:
- Nov 14, 2026
Figures from SEC filing, Wikidata, value.today research, Wikipedia; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Alimera Sciences? Verify and update this profile — free
Show Alimera Sciences's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.